Showing results (211-220 of 352) with videos related to
Sort By:
Pageof 36
Allergy and Asthma Proceedings|March 9, 2018
Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United StatesPaul Williams, Abhishek Kavati, Dominic Pilon, et al.Advances in Therapy|January 19, 2023
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US PopulationJeffrey S Berger, Veronica Ashton, François Laliberté, et al.Journal of Managed Care & Specialty Pharmacy|June 29, 2021
Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychoticsDominic Pilon, Charmi Patel, Marie-Hélène Lafeuille, et al.Journal of Affective Disorders|May 21, 2022
Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United StatesMaryia Zhdanava, Jennifer Voelker, Dominic Pilon, et al.Hospital Practice (1995)|September 26, 2014
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapiesFrançois Laliberté, Dominic Pilon, Monika K Raut, et al.Journal of Medical Economics|September 22, 2015
Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarinGeno J Merli, Judd E Hollander, Patrick Lefebvre, et al.Journal of Medical Economics|December 22, 2018
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trialsRhiannon Kamstra, Mike Durkin, Jennifer Cai, et al.Journal of Managed Care Pharmacy : JMCP|May 9, 2009
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspectiveFrancoiş Laliberté, Brahim K Bookhart, Francis Vekeman, et al.Journal of Medical Economics|January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiationDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.Pageof 36